[7:45-8:00 AM] Welcome to IWWM-13

Ranjana Advani, Stephen Ansell, Prashant Kapoor, and Steven Treon [Workshop Organizers]

 

 

[8:00-8:30 AM] Session I 

Keynote Lecture

 

Revised ICL/WHO Classification of WM and IGM Related Disorders

Keynote Speaker: James Cook, Loyola University, United States

Keynote Moderator: Steven Treon, Dana Farber Cancer Institute, United States

 

[8:30-9:30 AM] Session II

Genomic Predispositions in WM

Tina Bagratuni, Zachary Hunter [Chairs]

 

Single Cell Analysis reveals multiple monoclonal populations in WM and its precursor stages

Minghao Dang, MD Anderson, United States

 

Multiclonal Disease Underlies Familial WM

Alberto Guijosa, Dana Farber Cancer Institute United States

 

Spatial Profiling Reveals Tumor Microenvironmental Alterations in Asymptomatic WM progression

Irene Ghobrial, Dana Farber Cancer Institute United States

 

Importance of 6Q loss revealed in a MYD88 Transgenic Model of WM

Ruben Carrasco, Dana Farber Cancer Institute United States

 

[9:10 AM] Panel Discussion, All Session II Speakers

 

[9:30-10:00 AM] Mid-Morning Break & Networking

 

[10:00-11:00 AM] Session III

Genomic Landscape of the WM Clone

Damien Roos-Weil, Romanos Pistofidis-Sklavenitis [Chairs]

 

Dissection of Intra-clonal Apoptotic regulation in WM

Cristina Frusteri, University of Verona, Italy

 

Genomic Evolution of WM across disease stages

Jithma Abeykoon, Mayo Clinic-Rochester, United States

 

Time dependent genomic evolution of WM revealed in the E-Score

Zachary Hunter, Dana Farber Cancer Institute, United States

 

Subtype specific evolutionary Trajectories in WM

Gareth Morgan, New York University-Langone, United States

 

[10:40 AM] Panel Discussion, All Session III Speakers

 

[11:00-12:00 PM] Session IV

High Risk Genomics in WM

Gareth Morgan, Ramon Garcia Sanz [Chairs]

 

Prognostic Significance of TP53 Mutations from the BIOWM Study

Marzia Varettoni, University of Pavia, Italy

 

Genomic Landscape of High-Risk WM Disease

David Moreno, University of Barcelona, Spain

 

High Risk Genomics in the Era of BTK-Inhibitors

Shuhui Yi, Chinese Academy of Medical Sciences, China

 

Double HIT TP53 Alterations Define Ultra High-Risk WM

Steve Treon, Dana Farber Cancer Institute, United States

 

[11:40 AM] Panel Discussion, All Session IV Speakers

 

[12:00-1:00 PM] LUNCH

 

Consensus Panel Breakout Sessions (For Panel Members)

PANEL 1: Defining Uniform Criteria for MRD Assessment in WM

PANEL 2: Response Criteria for Non-IgM LPL Incl. Hyposecretory/Non-secretory

 

 

[1:00-2:00 PM] Session V

Tumor Immune Microenvironment

Stephen Ansell, Samir Parekh [Chairs]

 

Evolution of Tumor Immune Microenvironment

Romanos Pistofidis-Sklavenitis, City of Hope, United States

 

Tumor Immune Microenvironmental Interactions in WM

Hao Sun, Dana Farber Cancer Institute, United States

 

Role of Myeloid derived Immune Cells in WM related Immune Suppression

Patricia Mondello, Mayo Clinic-Rochester, United States

 

Distinct Immune and Genomic Signatures Predict Resistance to Ibrutinib Therapy in Waldenstrom’s macroglobulinemia

Tina Bagratuni, University of Athens, Greece

 

[1:40 PM] Panel Discussion, All Session V Speakers

 

 

[2:00-3:00 PM] Session: VI

Signaling Networks and Novel Targets in WM

Ken Anderson, Noopur Raje [Chairs]

 

Targeting IRAK signaling in MYD88 Mutated Lymphomas

John Hatcher, Dana Farber Cancer Institute, United States

 

Targeting HCK in BTK-Inhibitor resistant MYD88 Mutates Lymphomas

Shirong Liu, Dana Farber Cancer Institute, United States

 

Mechanistic Insights into Abrogating T-Cell exhaustion from A MYD88 Mutated Transgenic Murine Model

Christelle Vincent-Faber, University of Limoges, France

 

Targeting Alarmins to Improve T-Cell Immunity and Cellular Therapy Outcomes in MM: Lessons for WM

Samir Parekh, MT Sinai Medical Center, United States

 

[2:40 PM] Panel Discussion, All Session VI Speakers

 

 

[3:00-3:30 PM] Mid-Afternoon Break & Networking

 

 

[3:30-4:30 PM] Session: VII

Plenary Session I

Oral Presentations- Basic and Translational

Nikhil Munshi, Marzia Varettoni [Chairs]

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

 

[4:10 PM] Panel Discussion, All Session VII Speakers

 

[4:30-5:00 PM] Session VIII 

Keynote Lecture

 

AI Powered Workflows for Blood Cancers

Keynote Speaker: Jansen Seheult, Mayo Clinic-Rochester, United States

Keynote Moderator: Stephen Ansell, Mayo Clinic-Rochester, United States

 

 

[6:00-10:00 PM] Opening Ceremonies and Awards Presentation

[5:30-6:00 PM] Buses depart from the Hotel

 

• Keynote Speaker: BeiGene, Inc.
• Presentation of the Peter S. Bing Humanitarian Award
• Presentation of Jan Gosta Waldenstrom Award
• Presentation of Robert A. Kyle Award

 

[8:00-9:00 AM] Session IX

Special Topics in WM

Stathis Kastritis, Shirley D’Sa [Chairs]

 

Management of Transformed WM

Eric Durot, CHU DE REIMS, France

 

Management of IgM Peripheral Neuropathy

Shayna Sarosiek, Dana Farber Cancer Institute, United States

 

Management of Bing Neel Syndrome

Naohiro Sekiguchi, National Disaster Medical Center, Japan

 

Management of WM related Amyloidosis

Monique Minnema, University of Utrecht, The Netherlands

 

[8:40 AM] Panel Discussion, All Session IX Speakers

 

 

 

[9:00-10:00 AM] Session X

Novel Approaches for Treatment Naïve WM- Clinical Studies I

Meletios Dimopoulos, Judith Trotman [Chairs]       

 

Prospective Randomized Study of DRC vs. Bortezomib-DRC (ECWM-1 Trial) in Treatment naïve WM

Pierre Morel, CHU Amiens Picardie, France

 

Prospective Study of Bortezomib, Ibrutinib and Rituximab (ECWM-2 Trial) in Treatment naïve WM

Christian Buske, University of Ulm, Germany

 

Prospective Study of Ibrutinib and Carfilzomib vs. Ibrutinib (CZAR-1) in Treatment naïve WM

Stathis Kastritis, University of Athens, Greece

 

Randomized Phase II Study of DRC vs. Venetoclax and Rituximab (VIWA-1 Trial) in Treatment naïve WM

Christian Buske, University of Ulm, Germany

 

[9:40 AM] Panel Discussion, All Session X Speakers

 

 

[10:00-10:30 AM] Mid-Morning Break & Networking

 

 

[10:30-11:30 AM] Session XI

Novel Approaches for Treatment naïve WM-Clinical Studies II

M.J. Kersten, Constantine Tam [Chairs]

 

Prospective Study of Bendamustine-Rituximab followed by Observation or maintenance Rituximab

Mathias Rummel, University of Giessen, Germany

 

Prospective Study of Bendamustine, Rituximab and Acalabrutinib in Treatment naïve WM

Neil Berinstein, Sunnybrook Health Sciences Center, Canada

 

Prospective Study of Bendamustine, Rituximab and Zanubrutinib in Treatment naïve WM-China Study

Lugui Qiu, Chinese Academy of Medical Sciences, China

 

Prospective Study of Bendamustine, Rituximab and Zanubrutinib in Treatment naïve WM- USA Study

Andrew Branagan, Massachusetts General Hospital, United States

 

[11:10 AM] Panel Discussion, All Session XI Speakers

 

[11:30-12:30] Session XII

Novel Approaches for Previously Treated WM

Moshe Gatt, Sheeba Thomas [Chairs]

 

Prospective Study of Pirtobrutinib monotherapy in previously treated WM

1. Lia Palomba, Memorial Sloane Kettering Cancer Center, United States

 

Prospective Study of Pirtobrutinib and Venetoclax in previously treated WM

Jorge Castillo, Dana Farber Cancer Institute, United States

 

Phase I Study of the BTK PROTAC BGB-16673 in relapsed refractory WM

John Seymour, Peter Maccallum Cancer Center, Australia

 

Prospective Study of the CD19-ADC Loncastuximab in Previously Treated WM

Shayna Sarosiek, Dana Farber Cancer Institute, United States

 

[12:10 PM] Panel Discussion, All Session XII Speakers

 

 

[12:30-1:30 PM] LUNCH

 

Consensus Panel Breakout Sessions (For Panel Members)

PANEL 3: Management of Peripheral Neuropathy in WM and IgM related Disorders

PANEL 4: Updated Recommendations for Management of Treatment naïve, symptomatic WM

 

[12:30-1:30 PM] Young Investigator Mentoring LUNCH

 

 

[1:30-2:30 PM] Session: XIII

Plenary Session II

Oral Presentations- Clinical Studies

Ranjana Advani, John Seymour [Chairs]

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

[2:10 PM] Panel Discussion, All Session XIII Speakers

 

 

[2:30-3:30 PM] Session XIV

Plenary Session III

Young Investigator [YIA] Oral Presentations

Andrew Branagan, Jospehine Vos [Chairs]

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

Presentations- TBD

Speaker-TBD

 

[3:10 PM] Panel Discussion, All Session XIV Speakers

 

[3:30-5:00 PM] Session XV

Poster Session & Reception

 

[6:00-8:00 PM] Faculty Dinner Reception

[6:00-10:00 PM} Palm Springs Street Fair Festival, Palm Canyon Drive

[5:30 PM] Departure in the Hotel Lobby

 

[8:00-10:00 AM] Session XVI

Great Debates in WM

Eva Kimby & Irene Ghobrial [Chairs]

 

[8:00-8:30 AM] Great Debate I

Should Family of Patients with Inherited WM Predisposition be Evaluated for WM and Related Disorders?

 

YES!  They should be evaluated

Sigurdur Kristinson, University of Iceland, Iceland

 

NO!  They should NOT be evaluated

Shirely D’Sa, University Hospital of London, United Kingdom

 

 

[8:30-9:00 AM] Great Debate II

Should TP53 Mutation Status be considered in Treatment Decisions?

 

YES! They should be considered

Jorge Castillo, Dana Farber Cancer Institute, United States

 

NO! They should NOT be considered

Christian Buske, University of Ulm, Germany

 

[9:00-9:30] Great Debate III

Should Chemo-immunotherapy be used before or after BTK-Inhibitors in WM?

 

They should be used BEFORE BTK Inhibitors

Meletios Dimopoulos, University of Athens, Greece

 

They should be used AFTER BTK Inhibitors

Alessandra Tedeschi, Niguarda Hospital, Italy

 

[9:30-10:00 AM] Great Debate IV

Do we still need stem cell transplantation in the era of targeted and cellular therapies in WM?

 

NO, we do not need stem cell transplantation

Constantine Tam, Alfred Hospital, Monash University, Australia

 

YES, we DO need stem cell transplantation

Charalampia Kyriakou, University College London Hospitals NHS Trust, United Kingdom

 

 

[10:00-10:30 AM] Mid-Morning Break & Networking

 

[10:30-11:30 AM] Session XVII

Clinical Trials in Progress for WM- Non-Cellular Therapies

Jeffrey Matous, Roger Owen [Chairs]

 

Randomized Clinical Trial of Ibrutinib vs. DRC in Treatment naïve WM: RAINBOW Trial

Rebecca Auer, Royal London Hospital, United Kingdom

 

Prospective Study of Pirtobrutinib, Rituximab, and Venetoclax (PROVEN Study) in Treatment naïve WM

1. Lia Palomba, Memorial Sloane Kettering Cancer Center, United States

 

Phase 2 Study of the BCL2 Inhibitor Sonrotoclax in relapsed refractory WM

Ramon Garcia Sanz, Universitario Gregorio Maranon De Madrid, Spain

 

Clinical Trial of Sonrotoclax and BGB-16673 in Treatment naïve and BTK-Inhibitor naïve WM: Sounder Trial

Judith Trotman, University of Sydney, Australia

 

[11:10 AM] Panel Discussion, All Session XVII Speakers

 

 

[12:30-1:30 PM] LUNCH

 

Consensus Panel Breakout Sessions (For Panel Members)

PANEL 5: Updated Recommendations for Management of Relapsed-Refractory WM

PANEL 6: Targets and Priorities for Advancing Cellular Therapies in WM

 

[12:30-5:00 PM] BLISS FAMILY WORKSHOP for Advancing Cellular Therapies in WM

 

[12:30-1:00 PM] Session XVIII 

 

Keynote Lecture 1

Bringing Cellular Therapies to WM: The Lymphoma Experience

Keynote Speaker: Jeremy Abramson, Mass General Hospital, United States

Keynote Moderator: Ranjana Advani, Stanford University, United States

 

Keynote Lecture 2

Bringing Cellular Therapies to WM: The Myeloma Experience

Keynote Speaker: Noopur Raje, Mass General Hospital, United States

Keynote Moderator: Prashant Kapoor, Mayo Clinic-Rochester, United States

 

[1:30-2:30 PM] Session XIX

Clinical Trials in Progress for WM- Cellular Therapies I

Hermann Einsele, Thomas Martin [Chairs]

 

Clinical Trial of the CD19 TCE AZD0486 in Previously Treated WM

Tarek Mouhieddine, Dana Farber Cancer Institute, United States

 

Clinical Trial of the CD20 TCE Epcoritamab in previously treated WM- USA Experience

Gottfried von Keudell, Beth Israel Deaconess Medical Center, United States

 

Clinical Trial of the CD20 TCE Epcoritamab in previously treated WM- European Experience

Josephine Vos, University of Amsterdam, The Netherlands

 

Randomized Study of Odronextamab vs. Odronextamab and Zanubrutinib in WM: MOZART TRIAL

Christian Buske, University of Ulm, Germany

 

[2:10 PM] Panel Discussion, All Session XIX Speakers

 

 

[2:30-3:30 PM] Session XX

Clinical Trials in Progress for WM- Cellular Therapies II

Jeremy Abramson, Noopur Raje [Chairs]

 

Clinical Trial of the BCMA TCE Etentamig in Previously Treated WM

Prashant Kapoor, Mayo Clinic-Rochester, United States

 

Clinical Trial of the BCMA TCE Teclistamab in Previously Treated WM

Andrew Branagan, Mass General Hospital, United States

 

Clinical Trial of Mosunetuzumab and Pirtobrutinib in previously treated WM

Naren Epperla, University of Utah, United States

 

Presentation-TBD

Speaker-TBD

 

[3:10 PM] Panel Discussion, All Session XX Speakers

 

 

[3:30-5:00 PM] Session XXI

Advisory Panel on Advancing Cellular Therapies in WM

Stephen Ansell, Steven Treon [Chairs] 

 

Prioritizing TCE and CAR T cell studies in WM: Which Options, and for Which patients?

Hermann Einsele, University of Wurzburg, Germany

 

Developing MRD response assessment tools for dynamic risk assessment in WM

Nikhil Munshi, Dana Farber Cancer Institute, United States

 

What’s next in the world of Cellular Therapies that WM can serve as a disease model?

Thomas Martin, University of San Francisco, United States

 

Can animal models help us identify and optimize cellular therapy options for WM?

Jose Martinz-Climent, University of Navarra, Spain

 

[4:40 PM] Panel Discussion, All Session XXI Speakers

 

[6:00-10:00 PM] Closing Ceremonies and Awards Presentation

[5:30-6:00 PM] Buses depart from the Hotel

 

• Presentation of the Young Investigator Awards
• Announcement and Welcome to IWWM-14, 2028